Sweating Reduced: Labs, Diagnosis, and Next Steps

What Reduced Sweating Actually Means

Sweating is the body's primary cooling mechanism. When sweat production drops below normal, heat accumulates internally, raising the risk of heat exhaustion and heat stroke. The medical terms are hypohidrosis (decreased sweating) and anhidrosis (absent sweating), and either can affect the entire body or isolated regions.

How Normal Sweating Works

Eccrine sweat glands number between 2 and 4 million across the human body, with highest density on the palms, soles, and forehead 1. These glands are innervated by postganglionic sympathetic cholinergic fibers. When core temperature rises by as little as 0.2°C, the hypothalamus activates these fibers to trigger sweat secretion. Any disruption along this pathway, from the hypothalamus to the gland itself, can reduce or abolish sweating.

Focal vs. Generalized Hypohidrosis

The distribution pattern matters clinically. Focal hypohidrosis (one limb or one side of the body) often points to a peripheral nerve lesion or localized skin disease. Generalized hypohidrosis suggests a systemic process such as autonomic neuropathy, a medication effect, or a central nervous system disorder. A 2019 review in the Journal of the American Academy of Dermatology noted that the distribution of sweat loss correlates with the site of neurological or dermatological pathology in over 80% of cases 2.

Why It Gets Overlooked

Patients rarely present with "I'm not sweating enough" as their chief complaint. They notice heat intolerance, facial flushing, or dizziness in warm environments instead. A study of 116 patients referred to an autonomic disorders clinic found that 67% had experienced symptoms for more than 2 years before diagnosis 3. This delay can have serious consequences: the inability to sweat raises heat stroke risk, particularly during exercise or in hot climates.

Common Causes of Reduced Sweating

Hypohidrosis is a symptom, not a diagnosis. Identifying the underlying cause determines treatment. The list of possible etiologies spans neurology, endocrinology, dermatology, and pharmacology.

Autonomic Neuropathy

Diabetic autonomic neuropathy is the single most common cause of acquired hypohidrosis in adults. According to the American Diabetes Association, cardiovascular autonomic neuropathy (which shares pathways with sudomotor dysfunction) affects approximately 20% of people with type 2 diabetes at diagnosis and up to 50% after 10 years of disease duration 4. Sudomotor testing in these patients frequently reveals distal-to-proximal sweat loss, matching the "stocking-glove" pattern seen in sensory neuropathy.

Other causes of autonomic neuropathy that impair sweating include amyloidosis, Sjögren syndrome, autoimmune autonomic ganglionopathy, and pure autonomic failure. Each has distinct diagnostic markers discussed in the labs section below.

Medications That Reduce Sweating

Drug-induced hypohidrosis is common and often reversible. Anticholinergic medications are the most frequent culprits because they block acetylcholine at the eccrine gland. The list includes oxybutynin, glycopyrrolate, tricyclic antidepressants (amitriptyline, nortriptyline), first-generation antihistamines, and some antipsychotics 5. Topiramate deserves special attention: a FDA safety communication highlighted cases of oligohidrosis and hyperthermia, particularly in pediatric patients 6.

A careful medication reconciliation is the fastest diagnostic step. If a patient started an anticholinergic drug 2 to 8 weeks before noticing heat intolerance, the temporal relationship is often sufficient.

Skin and Sweat Gland Disorders

Conditions that physically damage or obstruct eccrine glands cause focal hypohidrosis. These include miliaria (heat rash with plugged sweat ducts), scleroderma, burns, radiation dermatitis, and ichthyosis. Ectodermal dysplasias, a group of over 200 genetic syndromes, can result in absent or sparse eccrine glands from birth 7.

Neurological Conditions

Ross syndrome (tonic pupil, areflexia, segmental anhidrosis), multiple system atrophy, and Parkinson disease all include sudomotor failure as a clinical feature. Horner syndrome causes ipsilateral facial anhidrosis due to disruption of the sympathetic chain. Spinal cord injuries produce anhidrosis below the level of the lesion, which contributes to dangerous thermoregulatory instability in affected individuals 8.

Which Labs and Tests to Request

A structured diagnostic approach prevents unnecessary testing while covering the most likely causes. The American Autonomic Society recommends combining clinical history with targeted blood work and functional sweat testing 9.

First-Line Blood Work

Begin with labs that screen for the most prevalent underlying conditions:

• HbA1c and fasting glucose: Rule out diabetic neuropathy. An HbA1c of 6.5% or higher confirms diabetes; values between 5.7% and 6.4% indicate prediabetes, which can also cause early sudomotor dysfunction 4.
• TSH and free T4: Hypothyroidism reduces metabolic rate and can decrease sweat output. Severe myxedema produces generalized hypohidrosis.
• ANA (antinuclear antibody): Screening for connective tissue diseases including Sjögren syndrome and scleroderma.
• ESR and CRP: Nonspecific inflammatory markers that, when elevated, prompt further autoimmune workup.
• Serum protein electrophoresis (SPEP): Screens for amyloidosis, a cause of autonomic neuropathy that is often missed.
• Anti-SSA/SSB antibodies: If Sjögren syndrome is suspected based on dry eyes, dry mouth, and hypohidrosis.

Second-Line and Specialized Labs

If first-line testing is unrevealing, consider:

• Ganglionic acetylcholine receptor (AChR) antibodies: Positive in approximately 50% of patients with autoimmune autonomic ganglionopathy, a treatable cause of widespread autonomic failure 10.
• Skin biopsy with intraepidermal nerve fiber density (IENFD): A 3-mm punch biopsy from the distal leg quantifies small fiber neuropathy. Values below the 5th percentile for age confirm the diagnosis 11.
• Genetic testing: Appropriate when clinical features suggest ectodermal dysplasia or hereditary sensory and autonomic neuropathy (HSAN).

Functional Sweat Testing

Blood work identifies the cause; sweat testing quantifies the deficit.

Thermoregulatory sweat test (TST): The patient is coated in an indicator powder (alizarin red or iodinated starch) and placed in a heated chamber. Areas that fail to sweat remain unchanged while sweating areas turn color. The result is a full-body sweat map that shows the precise distribution of anhidrosis. The test has high sensitivity for both focal and generalized patterns 12.

QSART (quantitative sudomotor axon reflex test): Iontophoresis of acetylcholine stimulates local sweat glands at four standardized sites (forearm, proximal leg, distal leg, foot). Sweat volume is measured in microliters. QSART is the most widely validated postganglionic sudomotor function test and is available at most academic autonomic laboratories 9.

Sympathetic skin response (SSR): An electrodiagnostic test that measures the electrical potential generated by sweat gland activity. It is less specific than QSART but more widely available.

A Diagnostic Decision Framework

This stepwise approach, used in the HealthRX clinical review process, organizes the workup by pretest probability.

Step 1: Medication Review

Check every current medication against anticholinergic burden scales such as the Anticholinergic Cognitive Burden (ACB) scale. If a high-burden drug was added within the past 3 months and the timeline matches symptom onset, a supervised trial discontinuation or substitution is the first intervention.

Step 2: Metabolic Screening

Order HbA1c, TSH/free T4, and basic metabolic panel. These three tests cover the two most common systemic causes (diabetes and thyroid disease) and are inexpensive.

Step 3: Autoimmune Panel

If metabolic screening is normal and the patient has any additional autonomic symptoms (orthostatic hypotension, gastroparesis, urinary retention), add ANA, anti-SSA/SSB, SPEP, and ganglionic AChR antibodies.

Step 4: Referral for Functional Testing

When blood work does not yield a diagnosis, refer to a neurology autonomic laboratory for TST and QSART. These tests confirm the deficit, map its distribution, and often narrow the differential. Dr. Wolfgang Singer, a neurologist at Mayo Clinic's Autonomic Disorders Program, has stated: "The thermoregulatory sweat test remains the most informative single test for evaluating the pattern and severity of sudomotor failure" 12.

Step 5: Biopsy

If functional testing confirms small fiber involvement but the cause remains unclear, a distal leg skin biopsy for IENFD can provide histopathological confirmation.

Treatment Options Based on Cause

Treatment targets the underlying condition. There is no FDA-approved drug that directly increases sweat production.

Treating the Underlying Condition

For diabetic neuropathy, the ADA's 2017 position statement recommends optimizing glycemic control as the primary intervention. In the DCCT/EDIC trial, intensive glucose management reduced the risk of confirmed clinical neuropathy by 30% over a median 13.3-year follow-up in type 1 diabetes 13. For type 2 diabetes, evidence supporting glycemic control as neuropathy prevention is less definitive, but HbA1c targets below 7% are still recommended.

For autoimmune autonomic ganglionopathy, case series have shown improvement with intravenous immunoglobulin (IVIG) or plasma exchange, particularly in patients with high ganglionic AChR antibody titers 10.

For medication-induced hypohidrosis, discontinuation or substitution resolves sweating in most patients within 2 to 6 weeks.

Cooling and Safety Strategies

While addressing the root cause, patients need practical heat management:

• Pre-cooling: Applying cold packs to the neck, axillae, and groin before outdoor activity reduces core temperature by 0.3 to 0.5°C 14.
• Evaporative cooling vests: These garments simulate the evaporative effect of sweating and can lower skin temperature by 3 to 5°C during wear.
• Hydration monitoring: Without visible sweat to signal fluid loss, patients may underestimate dehydration. Structured fluid intake (250 mL every 20 minutes during exertion) is a practical guideline.
• Environmental modification: Keeping indoor temperatures below 24°C (75°F) and using fans or air conditioning during warm months.

The Endocrine Society's clinical practice guidelines note that "patients with documented sudomotor failure should receive individualized counseling on heat avoidance, as even moderate environmental temperatures can precipitate heat illness in this population" 15.

When Sweating Does Not Return

In progressive conditions such as multiple system atrophy or advanced diabetic neuropathy, sweat function may not recover. Long-term management focuses on preventing hyperthermia. Occupational therapy assessments for heat-safe work environments and medical alert identification are appropriate for patients with generalized anhidrosis.

When to Seek Emergency Care

Reduced sweating becomes a medical emergency when thermoregulation fails completely. Heat stroke occurs when core body temperature exceeds 40°C (104°F) and the central nervous system shows signs of dysfunction (confusion, seizures, loss of consciousness). The CDC reports approximately 702 heat-related deaths annually in the United States, with impaired sweating as a recognized risk factor 16.

Red-Flag Symptoms

Seek immediate evaluation if reduced sweating is accompanied by:

• Core temperature above 39.5°C (103°F) that does not respond to passive cooling
• Confusion, slurred speech, or loss of consciousness
• Rapid heart rate with orthostatic blood pressure drop greater than 20 mmHg systolic
• New-onset widespread anhidrosis following a febrile illness (suggests acute autonomic neuropathy)

Hospital-Level Interventions

Emergency departments treat heat stroke with aggressive external cooling (ice water immersion targeting core temperature below 39°C within 30 minutes) and IV fluid resuscitation. Patients with confirmed anhidrosis should carry documentation of their condition so that emergency clinicians recognize the underlying vulnerability.

Monitoring and Follow-Up

After diagnosis, follow-up testing frequency depends on the cause.

For Diabetic Autonomic Neuropathy

The ADA recommends annual screening for autonomic symptoms in patients with type 2 diabetes beginning at diagnosis and in type 1 diabetes beginning 5 years after diagnosis 4. HbA1c should be checked every 3 months until at target, then every 6 months. QSART can be repeated annually to track progression or improvement.

For Medication-Induced Hypohidrosis

If a suspected medication is discontinued, reassess sweating at 4 and 8 weeks. If sweating normalizes, the causal link is confirmed. Document the adverse reaction in the patient's allergy and intolerance list to prevent re-challenge.

For Autoimmune Causes

Monitor ganglionic AChR antibody titers every 6 months in patients receiving immunotherapy. Clinical improvement, measured by QSART sweat volumes, typically lags behind antibody titer reductions by 3 to 6 months.

Patients with confirmed generalized anhidrosis of any cause should have a thermoregulation safety plan reviewed at every primary care visit during the months preceding summer. The plan should include a written action threshold: if core temperature measured by tympanic or rectal thermometer reaches 38.5°C (101.3°F) during activity, stop and begin active cooling immediately.